Chondroprotective agents
AssigneeKureha Chemical Industry Co., Ltd.
InventorsKoju Watanabe, Koichi Niimura, Kiyonori Umekawa
Life of this patent
Estimating the term…
Abstract
A chondroprotective agent comprising a flavonoid compound of the general formula (I): wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.
Claims9
A method for treating arthropathy, comprising administering to a mammal in need of a chondroprotective agent an effective amount of a chondroprotective agent comprising a glycoside of a compound of the formula (I):
- wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof,
- and a pharmaceutically acceptable carrier, said arthropathy being rheumatoid arthritis, osteoarthritis, periarthritis humeroscapularis, shoulder-arm-neck syndrome, or lumbago.
A method for reducing destruction of an articular cartilage in a patient suffering from arthropathy, comprising administering an effective amount of a chondroprotective agent comprising a glycoside compound of the formula (I):
- wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof,
- and a pharmaceutically acceptable carrier, said arthropathy being rheumatoid arthritis, osteoarthritis, periarthritis humeroscapularis, shoulder-arm-neck syndrome, or lumbago.
A method for reducing proteoglycan depletion in an articular cartilage of a patient suffering from arthropathy, comprising administering an effective amount of a chondroprotective agent comprising a glycoside compound of the formula (I):
- wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof,
- and a pharmaceutically acceptable carrier, said arthropathy being rheumatoid arthritis, osteoarthritis, periarthritis humeroscapularis, shoulder-arm-neck syndrome, or lumbago.
Dependencies are inferred from the claim text.